Adaptive Biotechnologies announced that clonoSEQ has received In Vitro Diagnostic Regulation 2017/746 Class C certification in the European Union.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Announces IVDR Certification for clonoSEQ® in European Union
- Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Adaptive Biotechnologies reports Q2 EPS (31c), consensus (33c)
- Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
- Cathie Wood’s ARK Investment buys 739K shares of Adaptive Biotechnologies today